The information published Thursday on the center’s Telegram channel specifies that all the research projects presented by BioCubaFarma are novel. Skolkovo is the Russian Innovation Center for the Development and Commercialization of Advanced Technologies.

It also pointed out that “the five proposals are innovative molecules, the first of their kind in the world”.

One of the proposals is a project of the Center for Research and Development of Medicines for the treatment of Parkinson’s disease. The initiative has received funding since 2018 for the sake of conducting preclinical studies and starting clinical trials in Russia.

“Also showing progress are companies Pelima, from the Center for Genetic Engineering and Biotechnology, and Alfanil, from the Center for Molecular Immunology, for the treatment of colorectal cancer and melanoma, respectively,” the publication added.

mh/arm/mem/gf